Richard Scott

Richard has over 25 years’ experience of Drug Discovery & Development in Project and Business Partnering roles. Originally a Biochemist & Computational Chemist by training, he has worked in Cambridgeshire for Start-up Biotechs (Peptide Therapeutics & DeNovo Pharmaceuticals) and Big Pharma (Amgen & GSK) before joining AZ in 2017. As part of the GPPM Late Oncology Team as Director of Global Project Management, Richard has managed AZ’s flagship Lung Cancer drug Tagrisso, overseeing R&D budgets of $1Bn. The most recent ADAURA clinical study read out 2 years ahead of planned results, had an accelerated submission & launch and was presented at the European Society for Medical Oncology in September for disease-free survival results. Richard now supports the Savolitinib program that combats Tagrisso resistance.